Thera-SAbDab

OLARATUMAB

>   Structural Summary
TherapeuticOlaratumab
TargetPDGFRA
Heavy ChainQLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedImClone Systems, Eli Lilly, Institute for Clinical Oncological Research
Conditions ApprovedSoft tissue sarcoma
Conditions ActivePancreatic cancer, Solid tumours
Conditions DiscontinuedGastrointestinal stromal tumours, Glioblastoma, Non-small cell lung cancer, Ovarian cancer, Prostate cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]